Feature S1 Biopharma to start Phase 2b study in female HSDD by yearend By Len Zehr Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with... June 14, 2016